[go: up one dir, main page]

SI2177536T1 - Protitelesa proti amiloidnemu peptidu beta - Google Patents

Protitelesa proti amiloidnemu peptidu beta

Info

Publication number
SI2177536T1
SI2177536T1 SI200731503T SI200731503T SI2177536T1 SI 2177536 T1 SI2177536 T1 SI 2177536T1 SI 200731503 T SI200731503 T SI 200731503T SI 200731503 T SI200731503 T SI 200731503T SI 2177536 T1 SI2177536 T1 SI 2177536T1
Authority
SI
Slovenia
Prior art keywords
antibodies against
beta peptide
against amyloid
amyloid
peptide
Prior art date
Application number
SI200731503T
Other languages
English (en)
Inventor
Stephen Anthony Burbidge
Jonathan Henry Ellis
Susannah K. Ford
Volker Germaschewski
Umesh Kumar
Karen Louise Philpott
Peter Ernest Soden
Original Assignee
Glaxo Group Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Limited filed Critical Glaxo Group Limited
Publication of SI2177536T1 publication Critical patent/SI2177536T1/sl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurosurgery (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
SI200731503T 2006-03-30 2007-03-27 Protitelesa proti amiloidnemu peptidu beta SI2177536T1 (sl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US78758806P 2006-03-30 2006-03-30
EP09178407.4A EP2177536B1 (en) 2006-03-30 2007-03-27 Antibodies against amyloid-beta peptide

Publications (1)

Publication Number Publication Date
SI2177536T1 true SI2177536T1 (sl) 2014-09-30

Family

ID=38284050

Family Applications (2)

Application Number Title Priority Date Filing Date
SI200731503T SI2177536T1 (sl) 2006-03-30 2007-03-27 Protitelesa proti amiloidnemu peptidu beta
SI200730173T SI1996621T1 (sl) 2006-03-30 2007-03-27 Protitelesa proti amiloidnemu peptidu beta

Family Applications After (1)

Application Number Title Priority Date Filing Date
SI200730173T SI1996621T1 (sl) 2006-03-30 2007-03-27 Protitelesa proti amiloidnemu peptidu beta

Country Status (32)

Country Link
US (3) US8227576B2 (sl)
EP (2) EP1996621B1 (sl)
JP (1) JP5103466B2 (sl)
KR (2) KR101263294B1 (sl)
CN (2) CN103539857A (sl)
AR (1) AR060332A1 (sl)
AT (1) ATE451392T1 (sl)
AU (1) AU2007233831B2 (sl)
BR (1) BRPI0709246A2 (sl)
CA (1) CA2647808C (sl)
CR (1) CR10347A (sl)
CY (1) CY1109877T1 (sl)
DE (1) DE602007003703D1 (sl)
DK (2) DK2177536T3 (sl)
EA (1) EA015654B9 (sl)
ES (2) ES2338179T3 (sl)
HR (2) HRP20100115T1 (sl)
IL (1) IL193695A (sl)
JO (1) JO2576B1 (sl)
MA (1) MA30337B1 (sl)
MX (1) MX2008012483A (sl)
MY (1) MY149630A (sl)
NO (1) NO20083793L (sl)
NZ (1) NZ571038A (sl)
PE (1) PE20080181A1 (sl)
PL (2) PL1996621T3 (sl)
PT (2) PT2177536E (sl)
SI (2) SI2177536T1 (sl)
TW (1) TWI385179B (sl)
UA (1) UA94734C2 (sl)
WO (1) WO2007113172A2 (sl)
ZA (1) ZA200807911B (sl)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080050367A1 (en) 1998-04-07 2008-02-28 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
TWI239847B (en) 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
PT1583562E (pt) 2003-01-06 2011-09-19 Angiochem Inc Angiopep-1, compostos relacionados, e suas utilizações
DE10303974A1 (de) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
ES2434732T3 (es) 2004-12-15 2013-12-17 Janssen Alzheimer Immunotherapy Anticuerpos para beta-amiloide humanizados para su uso en mejorar la cognición
WO2006081171A1 (en) 2005-01-24 2006-08-03 Amgen Inc. Humanized anti-amyloid antibody
DK1976877T4 (en) 2005-11-30 2017-01-16 Abbvie Inc Monoclonal antibodies to amyloid beta protein and uses thereof
CA2628703C (en) 2005-11-30 2019-10-29 Abbott Laboratories Anti-a.beta. globulomer antibodies, antigen-binding moieties thereof, corresponding hybridomas, nucleic acids, vectors, host cells, methods of producing said antibodies, compositions comprising said antibodies, uses of said antibodies and methods of using said antibodies
US8784810B2 (en) 2006-04-18 2014-07-22 Janssen Alzheimer Immunotherapy Treatment of amyloidogenic diseases
PL2468770T3 (pl) * 2006-07-14 2018-07-31 Ac Immune S.A. Humanizowane przeciwciało przeciw amyloidowi beta
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
WO2008104386A2 (en) 2007-02-27 2008-09-04 Abbott Gmbh & Co. Kg Method for the treatment of amyloidoses
US7931899B2 (en) 2007-05-14 2011-04-26 Medtronic, Inc Humanized anti-amyloid beta antibodies
US8323654B2 (en) 2007-05-14 2012-12-04 Medtronic, Inc. Anti-amyloid beta antibodies conjugated to sialic acid-containing molecules
US9365634B2 (en) 2007-05-29 2016-06-14 Angiochem Inc. Aprotinin-like polypeptides for delivering agents conjugated thereto to tissues
US8613923B2 (en) 2007-06-12 2013-12-24 Ac Immune S.A. Monoclonal antibody
US8048420B2 (en) 2007-06-12 2011-11-01 Ac Immune S.A. Monoclonal antibody
SI2182983T1 (sl) * 2007-07-27 2014-09-30 Janssen Alzheimer Immunotherapy Zdravljenje amiloidogenih bolezni s humaniziranimi protitelesi proti abeta
EA022990B1 (ru) * 2007-08-20 2016-04-29 Глаксо Груп Лимитед Способ получения клеточной линии млекопитающего, продуцирующей терапевтический белок
GB0718737D0 (en) * 2007-09-25 2007-11-07 Glaxo Group Ltd Antibodies
WO2009048537A2 (en) * 2007-10-05 2009-04-16 Genentech, Inc. Humanized antibody
DK2238166T3 (da) 2007-10-05 2014-01-27 Ac Immune Sa Anvendelse af et anti-amyloid-beta-antistof ved øjensygdomme
MX2010003622A (es) * 2007-10-12 2010-04-14 Hoffmann La Roche Expresion proteinica a partir de acidos nucleicos multiples.
JO3076B1 (ar) * 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap نظم العلاج المناعي المعتمد على حالة apoe
WO2009070648A2 (en) * 2007-11-27 2009-06-04 Medtronic, Inc. Humanized anti-amyloid beta antibodies
UY31520A1 (es) * 2007-12-11 2009-08-03 Proteinas de union a antigenos
EP2261254A3 (en) * 2007-12-21 2011-04-13 Amgen, Inc Anti-amyloid antibodies and uses thereof
TW201012489A (en) 2008-05-06 2010-04-01 Glaxo Group Ltd Encapsulation of biologically active agents
CN102245642A (zh) 2008-10-15 2011-11-16 安吉奥开米公司 Glp-1激动剂的结合物及其用途
US9067981B1 (en) 2008-10-30 2015-06-30 Janssen Sciences Ireland Uc Hybrid amyloid-beta antibodies
BRPI0922689A2 (pt) 2008-12-05 2018-11-06 Angiochem Inc. conjugados de neurotensina ou análogos de neurotensina e usos dos mesmos
ES2729261T3 (es) 2009-04-20 2019-10-31 Angiochem Inc Tratamiento del cáncer de ovario utilizando un agente anticancerígeno conjugado con un análogo de Angiopep-2
JP5932642B2 (ja) * 2009-07-02 2016-06-08 アンジオケム インコーポレーテッド 多量体ペプチドコンジュゲートおよびその使用
PL2475428T3 (pl) 2009-09-11 2015-12-31 Probiodrug Ag Pochodne heterocykliczne jako inhibitory cyklazy glutaminowej
EP2308897A1 (en) * 2009-10-09 2011-04-13 Pierre Fabre Medicament Chimeric antibodies specific for CD151 and use thereof in the treatment of cancer
EP2542579A1 (en) 2010-03-03 2013-01-09 Boehringer Ingelheim International GmbH Biparatopic abeta binding polypeptides
CN104744591B (zh) 2010-04-15 2022-09-27 Abbvie德国有限责任两合公司 β淀粉样蛋白结合蛋白
WO2011149461A1 (en) * 2010-05-27 2011-12-01 Medtronic, Inc. Anti-amyloid beta antibodies conjugated to sialic acid-containing molecules
AU2011282536B2 (en) 2010-07-30 2015-12-24 Ac Immune S.A. Safe and functional humanized anti beta-amyloid antibody
WO2012024187A1 (en) 2010-08-14 2012-02-23 Abbott Laboratories Amyloid-beta binding proteins
BR112013013083A2 (pt) 2010-11-30 2016-12-13 Genentech Inc métodos para transportar um composto, para aumentar exposição do cns a um composto, para diminuir a depuração de um composto, para aumentar a retenção no cns de um composto, para otimizar a farmacocinética, para tratar um distúrbio neurológico em um mamífero, para desenvolver um anticorpo, anticorpo, fragmento de anticorpo, anticorpo multiespecífico e uso de um anticorpo
US8703137B2 (en) 2011-01-31 2014-04-22 Intellect Neurosciences Inc. Treatment of tauopathies
EP2699596A4 (en) 2011-04-22 2015-01-14 Emergent Product Dev Seattle PROSTATE-SPECIFIC MEMBRANE-BINDING PROTEINS AND COMPOSITIONS AND METHOD THEREFOR
GB201113570D0 (en) 2011-08-05 2011-09-21 Glaxosmithkline Biolog Sa Vaccine
KR102031317B1 (ko) 2012-05-21 2019-10-14 제넨테크, 인크. 혈액-뇌 장벽 수송의 안전성을 개선하는 방법
RU2509155C1 (ru) * 2012-10-25 2014-03-10 Федеральное государственное бюджетное учреждение науки Институт биохимии им. А.Н. Баха Российской академии наук Способ детекции белков в амилоидном состоянии и набор для детекции белков в амилоидном состоянии
WO2014203188A2 (en) 2013-06-19 2014-12-24 Glaxosmithkline Intellectual Property (No.2) Limited Novel assay
CN104558172A (zh) * 2015-01-04 2015-04-29 东南大学 一种针对β淀粉样蛋白的单域重链纳米抗体及其应用
CN107921143B (zh) 2015-06-15 2021-11-19 安吉奥开米公司 用于治疗软脑膜癌病的方法
BR112018005573A2 (pt) 2015-09-21 2019-01-22 Aptevo Research And Development Llc ?polipeptídeos de ligação a cd3?
WO2017072090A1 (en) * 2015-10-27 2017-05-04 Glaxosmithkline Intellectual Property Development Limited Combination therapy
IL271488B2 (en) 2017-06-29 2024-06-01 Univ Columbia Chimeric antibodies for the treatment of diseases characterized by amyloid deposition
US11382974B2 (en) 2017-08-01 2022-07-12 The Trustees Of Columbia University In The City Of New York Methods and compositions for treatment of amyloid deposition diseases
DK3461819T3 (da) 2017-09-29 2020-08-10 Probiodrug Ag Inhibitorer af glutaminylcyklase
US12018069B2 (en) 2018-06-28 2024-06-25 The Trustees Of Columbia University In The City Of New York Methods and compositions for imaging amyloid deposits
CN111094340B (zh) * 2018-07-17 2022-11-22 江苏恒瑞医药股份有限公司 抗Abeta抗体、其抗原结合片段及应用
WO2020201828A1 (en) 2019-04-05 2020-10-08 Tauc3 Biologics Limited Anti-tauc3 antibodies and uses thereof
MX2023000949A (es) 2020-07-23 2023-02-22 Othair Prothena Ltd Anticuerpos anti-beta-amiloide (abeta).
TW202300517A (zh) 2021-03-12 2023-01-01 美商美國禮來大藥廠 抗類澱粉β抗體及其用途
WO2022251048A1 (en) 2021-05-24 2022-12-01 Eli Lilly And Company Anti-amyloid beta antibodies and uses thereof
CN114591918B (zh) * 2022-05-07 2022-07-26 北京第一生物化学药业有限公司 产生抗β-淀粉样蛋白抗体的杂交瘤细胞及其用途
CN114591917B (zh) * 2022-05-07 2022-09-02 北京第一生物化学药业有限公司 产生结合β-淀粉样蛋白的抗体的杂交瘤细胞及其用途
KR102530956B1 (ko) * 2022-09-08 2023-05-11 주식회사 알츠코리아 아밀로이드 베타 유래 에피토프를 유효성분으로 포함하는 알츠하이머성 치매 백신 조성물 및 이의 용도
CN118638219B (zh) * 2024-08-19 2024-11-22 成都迈科康生物科技有限公司 一种抗轮状病毒vp8蛋白的抗体或其抗原结合片段、抗体偶联物、核酸、载体、细胞及其应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5811517A (en) * 1992-01-27 1998-09-22 Icos Corporation ICAM-related protein variants
WO1998044955A1 (en) * 1997-04-09 1998-10-15 Mindset Ltd. Recombinant antibodies specific for beta-amyloid ends, dna encoding and methods of use thereof
US7179892B2 (en) * 2000-12-06 2007-02-20 Neuralab Limited Humanized antibodies that recognize beta amyloid peptide
AU1742200A (en) * 1998-11-25 2000-06-13 Eli Lilly And Company Prevention and treatment of amyloid-associated disorders
WO2001062801A2 (en) * 2000-02-24 2001-08-30 Washington University Humanized antibodies that sequester amyloid beta peptide
WO2002038108A2 (en) * 2000-11-03 2002-05-16 The J. David Gladstone Institutes Methods of treating disorders related to apoe
WO2004029629A1 (en) * 2002-09-27 2004-04-08 Janssen Pharmaceutica N.V. N-11 truncated amyloid-beta nomoclonal antibodies, compositions, methods and uses
ITTO20020867A1 (it) * 2002-10-08 2004-04-09 Pro Cord Spa Schienale di sedia.
CA2501945A1 (en) * 2002-10-09 2004-04-22 Rinat Neuroscience Corp. Methods of treating alzheimer's disease using antibodies directed against amyloid beta peptide and compositions thereof

Also Published As

Publication number Publication date
EA015654B1 (ru) 2011-10-31
NZ571038A (en) 2011-03-31
CY1109877T1 (el) 2014-09-10
US9193784B2 (en) 2015-11-24
EA200801842A1 (ru) 2009-02-27
TW200815466A (en) 2008-04-01
MY149630A (en) 2013-09-13
DK2177536T3 (da) 2014-07-14
AU2007233831A1 (en) 2007-10-11
EP2177536A1 (en) 2010-04-21
ATE451392T1 (de) 2009-12-15
SI1996621T1 (sl) 2010-04-30
EA015654B9 (ru) 2012-01-30
HRP20140618T1 (hr) 2014-08-15
HK1122311A1 (en) 2009-05-15
ES2484967T3 (es) 2014-08-12
JP2009531380A (ja) 2009-09-03
CR10347A (es) 2008-10-29
ZA200807911B (en) 2009-11-25
JO2576B1 (en) 2011-02-27
PL2177536T3 (pl) 2014-11-28
US8227576B2 (en) 2012-07-24
DE602007003703D1 (de) 2010-01-21
PL1996621T3 (pl) 2010-05-31
KR20080113273A (ko) 2008-12-29
KR20120093400A (ko) 2012-08-22
UA94734C2 (ru) 2011-06-10
KR101263294B1 (ko) 2013-06-04
ES2338179T3 (es) 2010-05-04
PT2177536E (pt) 2014-08-22
CN101415729B (zh) 2013-09-04
WO2007113172A2 (en) 2007-10-11
PE20080181A1 (es) 2008-03-16
CA2647808C (en) 2015-11-17
CA2647808A1 (en) 2007-10-11
US20110142824A1 (en) 2011-06-16
JP5103466B2 (ja) 2012-12-19
BRPI0709246A2 (pt) 2011-07-12
US20140050719A1 (en) 2014-02-20
CN103539857A (zh) 2014-01-29
US20160024197A1 (en) 2016-01-28
TWI385179B (zh) 2013-02-11
MX2008012483A (es) 2008-10-10
DK1996621T3 (da) 2010-04-19
EP1996621B1 (en) 2009-12-09
IL193695A (en) 2012-05-31
AU2007233831B2 (en) 2013-02-14
NO20083793L (no) 2008-10-13
PT1996621E (pt) 2010-03-08
WO2007113172A3 (en) 2007-11-29
MA30337B1 (fr) 2009-04-01
EP2177536B1 (en) 2014-06-04
HK1138015A1 (en) 2010-08-13
CN101415729A (zh) 2009-04-22
IL193695A0 (en) 2011-08-01
AR060332A1 (es) 2008-06-11
EP1996621A2 (en) 2008-12-03
HRP20100115T1 (hr) 2010-04-30

Similar Documents

Publication Publication Date Title
ZA200807911B (en) Antibodies against amyloid-beta peptide
IL196806A0 (en) Anti-myostatin antibodies
IL189580A0 (en) Anti-myostatin antibodies
IL189579A0 (en) Anti-myostatin antibodies
IL194165A0 (en) Glycosylated antibodies
EP2017283A4 (en) Peptides
GB0615662D0 (en) Antibody
GB0611116D0 (en) Proteins
EP2015785A4 (en) ANTIGEN AGRM2
GB0601976D0 (en) Proteins
GB0620735D0 (en) Proteins
GB0618748D0 (en) Peptide
IL197675A0 (en) Peptides
GB0605774D0 (en) Peptide
GB0612443D0 (en) Protein
GB0620304D0 (en) Protein
GB0614682D0 (en) Proteins
GB0612623D0 (en) Proteins
GB0606276D0 (en) Antibodies
GB0607376D0 (en) Antibodies
GB0625176D0 (en) Peptides
GB0609921D0 (en) Peptides
GB0609920D0 (en) Peptides
GB0618512D0 (en) Peptides
GB0614683D0 (en) Protein